The study has not yet undergone peer review.Ĭost is another concern.The 3-month duration of the study, supported by drugmaker AbbVie, was too short to evaluate the long-term efficacy and safety.Another 7 percent reported some nausea.About 10 percent of the participants given the drug developed constipation.“These results are exciting, as migraine can be debilitating, and this treatment led to fewer days with migraine for people who had already tried up to four other types of drugs to prevent migraine and either had no improvement or had side effects that outweighed any benefits,” study author, Patricia Pozo-Rosich, MD, PhD, at Vall d’Hebron University Hospital in Barcelona, Spain, said in a press release. They were also more likely to achieve a 50 percent or higher reduction in sick days per month. Those who were given the drug took other medications less often to stop an attack. The half of the participants who took 60 milligrams of atogepant once a day averaged four fewer migraine days per month versus two fewer for the placebo group. Of those, 44 percent had previously taken three or more classes of preventive drugs with no relief.Ĭircadian Rhythms Bring on Headache BluesĪssociation Between Computer Vision Syndrome, Insomnia, and Migraine Participants had unsuccessfully tried at least two other classes of drugs for prevention. The study followed 309 people who reported at least four migraine days during the month leading up to the study. In previous trials, this type of medication reduced frequency, severity, and duration of episodes.
They inhibit the calcitonin gene-related peptide receptor in the sensory nerves, a molecule believed to play a key role in migraine pathophysiology. The drug atogepant prevented migraine for patients who have had no success with other preventive drugs, according to the preliminary evidence presented at the American Academy of Neurology’s 75th Annual Meeting in Boston.Ītogepant belongs in a relatively new class of drugs known as CGRP antagonists. The migraine drug is costly at more than $1000 a month for a supply.Ī new drug could offer hope to people with migraine headache who don’t respond well to other medications.Constipation and nausea were the most common side effects.Users were also able to cut back on the amount of medication they needed to stop an attack and were also more likely to achieve a 50 percent or higher reduction in migraine days per month.A CGRP inhibitor called atogepant significantly prevented the number of headaches per month compared to a placebo.
Clinical Relevance: There could soon be another option for migraine patients
0 kommentar(er)
